Fresenius Medical Care Valuation
Is FME undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
3/6Valuation Score 3/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of FME when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: FME (CHF34.38) is trading below our estimate of fair value (CHF121.45)
Significantly Below Fair Value: FME is trading below fair value by more than 20%.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for FME?
Key metric: As FME is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.
| What is FME's PE Ratio? | |
|---|---|
| PE Ratio | 18.6x |
| Earnings | €658.94m |
| Market Cap | €12.23b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 1.2x |
| Enterprise Value/EBITDA | 9.6x |
| PEG Ratio | 1x |
Price to Earnings Ratio vs Peers
How does FME's PE Ratio compare to its peers?
| Company | Forward PE | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 45.2x | ||
GALE Galenica | 22.4x | 5.3% | CHF 3.8b |
STMN Straumann Holding | 61.3x | 20.9% | CHF 17.6b |
SOON Sonova Holding | 31.4x | 8.7% | CHF 18.9b |
YPSN Ypsomed Holding | 65.7x | 40.6% | CHF 4.9b |
FME Fresenius Medical Care | 18.6x | 19.3% | CHF 12.2b |
Price-To-Earnings vs Peers: FME is good value based on its Price-To-Earnings Ratio (18.6x) compared to the peer average (45.2x).
Price to Earnings Ratio vs Industry
How does FME's PE Ratio compare vs other companies in the European Healthcare Industry?
| 2 Companies | Price / Earnings | Estimated Growth | Market Cap |
|---|---|---|---|
| 2 Companies | Estimated Growth | Market Cap | |
|---|---|---|---|
Price-To-Earnings vs Industry: FME is expensive based on its Price-To-Earnings Ratio (18.6x) compared to the European Healthcare industry average (18.6x).
Price to Earnings Ratio vs Fair Ratio
What is FME's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PE Ratio | 18.6x |
| Fair PE Ratio | n/a |
Price-To-Earnings vs Fair Ratio: Insufficient data to calculate FME's Price-To-Earnings Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
COLTENE Holding
CHF 305.9m
Develops, manufactures, and sells disposables, tools, and equipment for dentists and dental laboratories in Europe, the Middle East, Africa, North America, Latin America, and Asia/Oceania.
CLTN
CHF 51.20
7D
-6.2%
1Y
-23.6%
Becton Dickinson
US$66.7b
Develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide.
912061
US$238.02
7D
0%
1Y
-2.2%
Galenica
CHF 3.8b
Operates as a healthcare service provider in Switzerland and internationally.
GALE
CHF 76.30
7D
-0.5%
1Y
8.2%